Cargando…
PB1773: MYBLOCK: A MYELOID BLOOD CANCER INITIATIVE
Autores principales: | Cairns, L., Clarke, K., Catherwood, M., Mills, K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430811/ http://dx.doi.org/10.1097/01.HS9.0000849948.39717.4f |
Ejemplares similares
-
PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
por: de Botton, Stéphane, et al.
Publicado: (2023) -
PB2340: INFLUENCE OF INITIAL CLINICAL FEATURES IN THERAPEUTIC DECISIONS AND DIAGNOSTIC PROCESS OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA. A REAL WORLD EXPERIENCE
por: Bolea, L., et al.
Publicado: (2022) -
PB1784: CYTOGENETIC LANDSCAPE OF 87 MOROCCAN ACUTE MYELOID LEUKEMIA PATIENTS
por: Mahtat, E. M., et al.
Publicado: (2022) -
PB1795: BIO-INSPIRED NANOMEDICINE FOR TARGETED ACUTE MYELOID LEUKEMIA IMMUNOTHERAPY
por: Wang, X., et al.
Publicado: (2022) -
PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)